Timothy B. Lowinger

3.8k citations

53 papers · 2.7k indexed · 1 hit paper · h-index 20

Impact in

Hepatology top 5%
- Hepatocellular Carcinoma Treatment and Prognosis
Cancer Research top 5%
- NF-κB Signaling Pathways

Papers in

Oncology 29
- HER2/EGFR in Cancer Research 19
- Cancer Treatment and Pharmacology 7
- CAR-T cell therapy research 5
Radiology, Nuclear Medicine and Imaging 20
- Monoclonal and Polyclonal Antibodies Research 17
- Radiopharmaceutical Chemistry and Applications 8

Co-authors: Roger A. Smith Jacques Dumas Scott M. Wilhelm Brian Schwartz Christopher Carter Susan L. Kelley Mark Lynch Ronit Simantov
Journals: Cancer Research (17 papers)Bioorganic & Medicinal Chemistry Letters (8 papers)The Journal of Organic Chemistry (4 papers)Molecular Cancer Therapeutics (2 papers)Nature Reviews Drug Discovery (2 papers)
Partner nations: United States Japan Germany

In The Last Decade

Timothy B. Lowinger

48 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer 2006 · 1.4k citations

Peers

Countries citing papers authored by Timothy B. Lowinger

Since Specialization

Citations

This map shows the geographic impact of Timothy B. Lowinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy B. Lowinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy B. Lowinger more than expected).

Fields of papers citing papers by Timothy B. Lowinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy B. Lowinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy B. Lowinger. The network helps show where Timothy B. Lowinger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Timothy B. Lowinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Timothy B. Lowinger Line = papers co-authored together Timothy B. Lowinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Constructing the cure: engineering the next wave of antibody and cellular immune therapies Journal for ImmunoTherapy of Cancer ·Stefanie R. Bailey, Eric Bartee, Kyle G. Daniels, Christopher R. Heery, Pravin T. P. Kaumaya, Gregory B. Lesinski, Timothy B. Lowinger, Michelle H. Nelson, Mark P. Rubinstein, Florence Fresen, Chrystal M. Paulos, Avery D. Posey	2025	0
2	PBPK Modeling to Predict Clinical Drug–Drug Interaction and Impact of Hepatic Impairment for an ADC With the Payload Auristatin F‐Hydroxypropylamide CPT Pharmacometrics & Systems Pharmacology ·Niyanta Kumar, Vaishali Dixit, Howard Burt, Katherine L. Gill, Hannah M. Jones, Natalie Keirstead, Dian Su, Dorin Toader, Timothy B. Lowinger	2025	0
3	Development of a Novel DNA Mono-alkylator Platform for Antibody–Drug Conjugates Molecular Cancer Therapeutics ·Joshua D. Thomas, M. Mantegazza, Mao Yin, Natalya D. Bodyak, Jephthah O. Osei, Marina Protopopova, B Rzegocinska-Tyzuk, Brian Jones, Liping Yang, Daniel Custar, Carlos González Baez, Damon R. Demady, Scott D. Collins, Ling Xu, A.L. Aspler, LiuLiang Qin, Elena Ter‐Ovanesyan, Marc Damelin, Dorin Toader, Timothy B. Lowinger	2024	0
4	Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses Nature Communications ·純一平野, Travis Monnell, Anette Iff, Pamela Shaw, R Lelandais, Carlos González Baez, Melissa Dolan, Rebecca Mosher, Mk., Chen‐Ni Chin, Dorin Toader, Jeremy R. Duvall, Raghida A. Bukhalid, Timothy B. Lowinger, Marc Damelin	2024	33
5	Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates Journal of Medicinal Chemistry ·Jeremy R. Duvall, Joshua D. Thomas, Raghida A. Bukhalid, Carlos González Baez, K. W. Bentley, Scott D. Collins, Timothy K. Eitas, Brian Jones, B Rzegocinska-Tyzuk, R Lelandais, Marina Protopopova, Soumya S. Ray, Elena Ter‐Ovanesyan, Ling Xu, Liping Yang, 掛見喜一郎, Marc Damelin, Dorin Toader, Timothy B. Lowinger	2023	32
6	Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates Bioorganic & Medicinal Chemistry Letters ·Joshua D. Thomas, M. Mantegazza, Mao Yin, Natalya D. Bodyak, Dmitry R. Gumerov, H Bridge, 久雄伊藤, Brian Jones, Marina Protopopova, LiuLiang Qin, Dea Levana, Damon R. Demady, Timothy B. Lowinger	2022	3
7	Abstract 2114: Tumor cell-targeted STING-agonist antibody-drug conjugates achieve potent anti-tumor activity by delivering STING agonist specifically to tumor cells andFcγRI-expressing subset of myeloid cells Cancer Research ·Naniye Mallı Cetinbas, Carlos González Baez, Travis Monnell, Anette Iff, K. W. Bentley, Susan M. Clardy, 김성준, 久雄伊藤, Marina Protopopova, Charles Dormoy, Joshua D. Thomas, Dea Levana, Dorin Toader, Jeremy R. Duvall, Raghida A. Bukhalid, Marc Damelin, Timothy B. Lowinger	2022	6
8	620 Tumor cell-intrinsic STING pathway is activated in the presence of cues from immune cells and contributes to the anti-tumor activity of tumor cell-targeted STING agonist antibody-drug conjugates SHILAP Revista de lepidopterología ·Naniye Mallı Cetinbas, Travis Monnell, Winnie Lee, Carlos González Baez, Chen‐Ni Chin, Pamela Shaw, Kelly L. Slocum, LiuLiang Qin, Y. Liu, K. W. Bentley, Susan M. Clardy, Brian Jones, B Rzegocinska-Tyzuk, Joshua D. Thomas, Rebecca Mosher, Dorin Toader, Jeremy R. Duvall, Raghida A. Bukhalid, Marc Damelin, Timothy B. Lowinger	2020	3
9	MA09.10 A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC Journal of Thoracic Oncology ·Donald A. Bergstrom, Natalya D. Bodyak, Joslyne Viquez, Laura L. Poling, Mao Yin, Marina Protopopova, LI Yue-ya, LiuLiang Qin, Dmitry R. Gumerov, Elena Ter‐Ovanesyan, Rebecca Mosher, Timothy B. Lowinger	2017	3
10	Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design Pharmacology & Therapeutics ·Pamela A. Trail, Gene M. Dubowchik, Timothy B. Lowinger	2017	98
11	A Polymer-Based Antibody–Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy Cancer Research ·Hengfeng Zhao, Mao Yin, Natalya D. Bodyak, Charles Dormoy, Joshua D. Thomas, Charles E. Hammond, LiuLiang Qin, Bangmin Zhu, Dmitry R. Gumerov, Elena Ter‐Ovanesyan, Dea Levana, Timothy B. Lowinger	2015	73
12	Abstract LB-231: A novel, highly potent HER2-targeted antibody-drug conjugate (ADC) for the treatment of low HER2-expressing tumors and combination with trastuzumab-based regimens in HER2-driven tumors Cancer Research ·Donald A. Bergstrom, Natalya D. Bodyak, Joslyne Viquez, Peter U. Park, Michael J. DeVit, Mao Yin, Laura L. Poling, Joshua D. Thomas, Dmitry R. Gumerov, Dongmei Xiao, Elena Ter‐Ovanesyan, LiuLiang Qin, Dea Levana, 八木美知子, Timothy B. Lowinger	2015	12
13	Naphthol derivatives as TRPV1 inhibitors for the treatment of urinary incontinence Bioorganic & Medicinal Chemistry Letters ·Klaus Urbahns, Takeshi Yura, Muneto Mogi, Masaomi Tajimi, Hiroshi Fujishima, Tsutomu Masuda, Sui-Wan Lee, Toshiya Moriwaki, Timothy B. Lowinger, Heinrich Meier, Fiona Chan, David J. Madge, Lalu Satria Utama	2011	8
14	Abstract #1572: Pharmacokinetics of a novel fumagillol conjugate XMT-1107 in the rat Cancer Research ·Joslyne Viquez, Yi-ke LI, Shaohua Wang, Mao Yin, H. Einsele, Robert J. Fram, Timothy B. Lowinger	2009	1
15	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nature Reviews Drug Discovery ·Scott M. Wilhelm, Christopher Carter, Mark Lynch, Timothy B. Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov, Susan L. Kelley Hit paper breakdown →	2006	1447
16	A selective novel low‐molecular‐weight inhibitor of IκB kinase‐β (IKK‐β) prevents pulmonary inflammation and shows broad anti‐inflammatory activity British Journal of Pharmacology ·Karl Ziegelbauer, Florian Gantner, Nicholas W. Lukacs, Aaron A. Berlin, Kinji Fuchikami, Toshiro Niki, Katsuya Sakai, M. Christina Velarde, Keisuke Takeshita, O Edgar Pérez, Hiroshi Komura, Toshiki Murata, Timothy B. Lowinger, Kevin B. Bacon	2005	125
17	Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents Bioorganic & Medicinal Chemistry Letters ·Toshiki Murata, Mitsuyuki Shimada, Sachiko Sakakibara, Takashi Yoshino, Tsutomu Masuda, Takuya Shintani, Hiroki Sato, Daniel Antonio Maruccio, Keiko Fukushima, Quentin Nakonechny, ENP Subong, Kinji Fuchikami, Hiroshi Komura, Akihiko Watanabe, Karl Ziegelbauer, Kevin B. Bacon, Timothy B. Lowinger	2004	101
18	Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach Bioorganic & Medicinal Chemistry Letters ·Roger A. Smith, J A Barbosa, Thaline Mairace Hernandez das Neves, Mark A. Bobko, Victor Oscar Eyo, Robert Dally, Jeffrey S. Johnson, Michael Katz, Abdelhak Nehar, Jill Kingery-Wood, Wendy Lee, Timothy B. Lowinger, John F. Lyons, Vivienne Marsh, Daniel H. Rogers, Maulina Kartika, Tracy L. Walling, Hanno Wild	2001	70
19	Discovery of a new class of p38 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Jacques Dumas, Robert Sibley, Bernd Riedl, S. G. Mamaev, Wendy Lee, Timothy B. Lowinger, Anikó M. Redman, Jeffrey S. Johnson, Jill Kingery-Wood, William J. Scott, Roger A. Smith, Mark A. Bobko, Robert Schoenleber, Gerald Ranges, Timothy J Housley, Ajay Bhargava, Scott M. Wilhelm, Alka Shrikhande	2000	34
20	1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors Bioorganic & Medicinal Chemistry Letters ·Jacques Dumas, Holia Hatoum‐Mokdad, Robert Sibley, Bernd Riedl, William J. Scott, S. G. Mamaev, Timothy B. Lowinger, Catherine A. Brennan, Reina Natero, Ma. de Jesús Vázquez García, Jeffrey S. Johnson, Robert Schoenleber, Ajay Bhargava, Scott M. Wilhelm, Timothy J Housley, Gerald Ranges, Alka Shrikhande	2000	47

About Timothy B. Lowinger

Timothy B. Lowinger is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Organic Chemistry, Immunology and Biotechnology, having authored 53 papers that have together received 2.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (19 papers), Monoclonal and Polyclonal Antibodies Research (17 papers), Radiopharmaceutical Chemistry and Applications (8 papers), Cancer Treatment and Pharmacology (7 papers), interferon and immune responses (5 papers), Synthesis and biological activity (5 papers), Melanoma and MAPK Pathways (5 papers) and CAR-T cell therapy research (5 papers). The work is most often cited by research in Hepatology (257 citations), Cancer Research (475 citations), Oncology (843 citations), Organic Chemistry (742 citations) and Molecular Biology (1.3k citations). Timothy B. Lowinger has collaborated with scholars based in United States, Japan and Germany. Frequent co-authors include Roger A. Smith, Jacques Dumas, Scott M. Wilhelm, Brian Schwartz, Christopher Carter, Susan L. Kelley, Mark Lynch, Ronit Simantov, Bernd Riedl and Pamela A. Trail. Their work appears in journals such as Cancer Research, Bioorganic & Medicinal Chemistry Letters, The Journal of Organic Chemistry, Molecular Cancer Therapeutics and Nature Reviews Drug Discovery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact